OncoMatch/Bladder Cancer (Urothelial)/PD-L1 (CD274)
Bladder Cancer (Urothelial)PD-L1 (CD274) Clinical Trials
Enfortumab vedotin plus pembrolizumab is now the FDA-approved first-line standard for advanced urothelial carcinoma regardless of PD-L1 status (EV-302/KEYNOTE-869, approved December 2023). For cisplatin-ineligible patients not receiving EV+pembro, PD-L1 expression (IC score ≥1% by SP142) guided atezolizumab eligibility; pembrolizumab monotherapy is approved in second-line disease regardless of PD-L1. Trials investigate novel checkpoint combinations, neoadjuvant IO strategies, and biomarker-refined patient selection.
Top recruiting PD-L1 (CD274) Bladder Cancer (Urothelial) trials
Ranked by phase and US site count.
See all trials matched to your profile →Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
Browse other molecular targets with active Bladder Cancer (Urothelial) trials.